The comparison of treating non-squamous lung cancer with either pemetrexed or docetaxel in addition to cisplatin has shown that the two combinations achieve similar progression-free survival. Although docetaxel was associated with more frequent adverse events. At the ESMO 2014 Congress in Madrid, Dr Young-Chul Kim from Chonnam National University Medical School, South Korea, reported the results of an open-label phase III trial that included 149 patients with non-squamous ...Sunday 5 October 2014
Pemetrexed or Docetaxel With Cisplatin Achieve Comparable Outcomes in Non-Squamous Lung Cancer
The comparison of treating non-squamous lung cancer with either pemetrexed or docetaxel in addition to cisplatin has shown that the two combinations achieve similar progression-free survival. Although docetaxel was associated with more frequent adverse events. At the ESMO 2014 Congress in Madrid, Dr Young-Chul Kim from Chonnam National University Medical School, South Korea, reported the results of an open-label phase III trial that included 149 patients with non-squamous ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment